Cemiplimab-rwlc (Libtayo®) Patient Management
Last Updated: September 29, 2023
By: Marko Skelin, MPharm, PhD | Luis Raez, MD, FACP
About this PQI
The purpose of this PQI is to discuss the option of using cemiplimab-rwlc for patients with:
1. Locally advanced or metastatic basal cell carcinoma (laBCC or mBCC) previously treated with a hedgehog pathway inhibitor (HHI) or for whom an HHI is not appropriate.
2. Locally advanced or metastatic cutaneous squamous cell carcinoma (laCSCC or mCSCC) who are not candidates for curative surgery or curative radiation.
3. First-line locally advanced non-small cell lung cancer (NSCLC) where patients are not candidates for surgical resection or definitive chemoradiation or metastatic NSCLC whose tumors have high PD-L1 expression [≥50%], with no EGFR, ALK, or ROS1 aberrations, and locally advanced or metastatic.
4. Firsts-line in combination with platinum-based chemotherapy in adult patients with advanced NSCLC with no EGFR, ALK, or ROS1 aberrations, and locally advanced or metastatic.
More About This PQI
PQI in Action Articles:
How to Use a Positive Quality Intervention (PQI)
Essentially, it’s a tool to improve patient care by sharing best practices in oncology care.
Consider this standardized, peer-review clinical guidance to oncology healthcare teams, enabling you and your team to consistently deliver high-quality care to your patients.
Find a PQI